Alfadhli Eman, Osman Eman, Basri Taghreed
Taibah University, Medina, Saudi Arabia.
Madina Maternity and Children Hospital, Medina, Saudi Arabia.
Diabetol Metab Syndr. 2016 Jul 26;8:48. doi: 10.1186/s13098-016-0161-5. eCollection 2016.
Women with gestational diabetes mellitus (GDM) are required to control their blood glucose shortly after GDM diagnosis to minimize adverse pregnancy outcomes. A real time-continuous glucose monitoring system (RT-CGMS) provides the patient with continuous information about the alterations in levels of the blood glucose. This visibility may empower the patient to modify her lifestyle and engage in therapeutic management. The aim of this study was to determine whether a single application of RT-CGMS to pregnant women shortly after GDM diagnosis is useful as an educational and motivational tool.
This study was a prospective open label randomized controlled study conducted at Maternity and Children Hospital, Medina, Saudi Arabia. A total of 130 pregnant women with GDM were randomised to either blood glucose self-monitor alone (SMBG group) (n = 62) or in addition to SMBG, patients wore a Guardian(®) REAL-Time Continuous Glucose Monitoring System (Medtronic MiniMed) once for 3-7 days, within 2 weeks of GDM diagnosis (RT-CGMS group) (n = 68). The primary outcomes were maternal glycemic control and pregnancy outcomes. Secondary outcomes were the changes in parameters of glucose variability, which includes mean sensor readings, standard deviation (SD) of blood glucose, and area under the curve for hyper and hypoglycaemia at the end of the RT-CGMS application.
HbA1c, mean fasting and postprandial glucose levels were similar in both groups at the end of the pregnancy. Pregnancy outcomes were comparable. However, there was significant improvement in the parameters of glucose variability on the last day of sensor application; both mean glucose and the SD of mean glycaemia were reduced significantly; P = 0.016 and P = 0.034, respectively. The area under the curve for hyper and hypoglycaemia were improved, however, the results were not statistically significant.
Although a single application of RT-CGMS shortly after GDM diagnosis is helpful as an educational tool, it was not associated with improvement in glycemic control or pregnancy outcomes.
妊娠期糖尿病(GDM)女性在确诊后需要尽快控制血糖,以尽量减少不良妊娠结局。实时连续血糖监测系统(RT-CGMS)能为患者提供血糖水平变化的连续信息。这种可见性可能使患者有能力改变其生活方式并参与治疗管理。本研究的目的是确定在GDM诊断后不久对孕妇单次应用RT-CGMS作为一种教育和激励工具是否有用。
本研究是在沙特阿拉伯麦地那妇幼医院进行的一项前瞻性开放标签随机对照研究。共有130例GDM孕妇被随机分为仅进行血糖自我监测组(SMBG组)(n = 62)或除SMBG外,在GDM诊断后2周内佩戴Guardian(®)实时连续血糖监测系统(美敦力MiniMed)一次,为期3 - 7天的组(RT-CGMS组)(n = 68)。主要结局是母体血糖控制和妊娠结局。次要结局是血糖变异性参数的变化,包括平均传感器读数、血糖标准差(SD)以及RT-CGMS应用结束时高血糖和低血糖的曲线下面积。
妊娠结束时,两组的糖化血红蛋白、平均空腹和餐后血糖水平相似。妊娠结局相当。然而,在传感器应用的最后一天,血糖变异性参数有显著改善;平均血糖和平均血糖标准差均显著降低;P分别为0.016和0.034。高血糖和低血糖的曲线下面积有所改善,但结果无统计学意义。
尽管在GDM诊断后不久单次应用RT-CGMS作为一种教育工具是有帮助的,但它与血糖控制或妊娠结局的改善无关。